Results 241 to 250 of about 1,428,732 (361)

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun   +4 more
wiley   +1 more source

Impact of Distributing Test Result Reports for Chronic Viral Hepatitis on Awareness of Hepatitis Testing Among Non-Specialist Physicians. [PDF]

open access: yesMedicina (Kaunas)
Itakura J   +8 more
europepmc   +1 more source

Psychoactive prescription drug use and misuse in patients on opioid agonist treatment

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims To identify the patterns and trends in prescription drug use and misuse in patients on opioid agonist treatment. Methods We used data from the OPPIDUM programme, which collects data from patients attending substance abuse treatment facilities. Data collected include use of psychoactive prescription drugs in the past week.
Thomas Soeiro   +5 more
wiley   +1 more source

Comparison of safety and immunogenicity between Healive®, Havrix® and live attenuated Hepatitis A vaccines in pediatric population: a systematic review with meta-analysis. [PDF]

open access: yesItal J Pediatr
Abo Zeid M   +10 more
europepmc   +1 more source

Safety and pharmacokinetics of a novel potent GABA analogue crisugabalin in Chinese subjects with various degrees of renal impairment

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Crisugabalin is a novel calcium channel α2δ subunit ligand and a highly selective oral gamma‐aminobutyric acid (GABA) analogue developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and postherpetic neuralgia (PHN). This study investigated pharmacokinetic properties and safety of crisugabalin in subjects with renal impairment ...
Shibeilei Lin   +6 more
wiley   +1 more source

A Decade of the National Center for HIV, Viral Hepatitis, STD, and TB Prevention's Epidemiologic and Economic Modeling Agreement. [PDF]

open access: yesPublic Health Rep
Abimbola TO   +10 more
europepmc   +1 more source

Epidermal Powder Immunization Induces both Cytotoxic T-Lymphocyte and Antibody Responses to Protein Antigens of Influenza and Hepatitis B Viruses

open access: green, 2001
Dexiang Chen   +7 more
openalex   +1 more source

Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim The benzoxaborole derivative DNDI‐6148 is an antiparasitic agent with activity against multiple Leishmania protozoan species, including L. infantum and L. donovani, which cause visceral leishmaniasis. We investigated the safety, tolerability and pharmacokinetics of single oral doses of DNDI‐6148 in a randomized, parallel‐group, placebo‐controlled ...
Jean‐Yves Gillon   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy